Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FIN-EGFR: real-world treatment outcomes by EGFR mutational subtypes in NSCLC in Southern Finland.

Acta oncologica (Stockholm, Sweden) - 23 Sept 2026

Knuuttila Aija, Ekblom Monica H, Nurmi Lalli O, Bonin Anna, Heikkilä Eija K, Silvoniemi Maria

Abstract excerpt

BACKGROUND AND PURPOSE: The aim of the study was to compare overall survival (OS) and time to next treatment (TTNT) of epidermal growth factor receptor (EGFR) mutation positive Non-Small Cell Lung Cancer (NSCLC) patients from start of first therapy, by EGFR mutational sub-type, disease stage at first diagnosis (early vs. advanced stage), first treatment and metastatic sites. Patient/material and methods: This...

Read the complete abstract on PubMed

Topics

Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Finland
Female
ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Male

Mutation

Retrospective Studies

Middle Aged

Aged

Treatment Outcome

Aged, 80 and over

Protein Kinase Inhibitors

Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 42776017
DOI: 10.2340/1651-226X.2026.46295
PMCID: PMC13615412

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FIN-EGFR: real-world treatment outcomes by EGFR mutational subtypes in NSCLC in Southern Finland.PMID 42776017Read ↗

FIN-EGFRprint: a Finnish real-world study on treatments and outcomes in advanced NSCLC with common EGFR mutations.Semantic proximity Read ↗

Clinical Impact of EGFR Mutation Subtypes on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: An Austrian Real-World StudySemantic proximity Read ↗

Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations.Semantic proximity Read ↗

Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI Therapy.Semantic proximity Read ↗

Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study.Semantic proximity Read ↗

The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.Semantic proximity Read ↗

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors: A single-center ambispective cohort study.Semantic proximity Read ↗

Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USASemantic proximity Read ↗

A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands.Semantic proximity Read ↗

Real-World Survival Outcomes in EGFR-Mutant Advanced NSCLC Treated With EGFR TKIs: Insights From a Single-Center Clinical Data Warehouse Analysis in South Korea.Semantic proximity Read ↗

Baseline predictors of early progression during EGFR-TKI therapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study.Semantic proximity Read ↗

EGFR testing practices, treatment choice and clinical outcomes in advanced NSCLC in a real-world setting: A retrospective analysis of a US-based electronic health records database.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.